[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchiectasis-with-acute-exacerbation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchiectasis-with-acute-exacerbation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,81,102,122,146,174,204,227],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":52},"100638185","phase-4-azithromycin-to-modify-bronchiectasis-exacerbation-risk-100638185",false,"NCT07608328","Azithromycin to Modify Bronchiectasis Exacerbation Risk","AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis","AMBER","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).\n* Diagnosis supported by clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, respiratory follow-up services, or routine bronchiectasis care pathways at Assiut University Hospitals during the enrollment period.\n* Suitable for baseline disease-signature assessment.\n* Able to undergo protocol-defined clinical, functional, radiological, oxygenation, inflammatory, symptom, and safety assessment.\n* Able to complete planned 12-month follow-up.\n* Eligible for randomization after baseline safety evaluation.\n* Written informed consent obtained from the participant or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment, baseline assessment, or randomization.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Known hypersensitivity, contraindication, or serious intolerance to azithromycin or macrolide therapy.\n* Baseline cardiac findings judged by the investigator to make long-term azithromycin unsafe.\n* Requirement for long-term maintenance macrolide therapy at enrollment.\n* Current long-term maintenance macrolide use that cannot be safely discontinued before enrollment.\n* Inability to complete required baseline disease-signature assessment.\n* Inability or unwillingness to complete planned 12-month follow-up.\n* Refusal to participate.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).\n\nThe trial evaluates whether azithromycin 250 mg orally once daily for 12 months, added to standard bronchiectasis care, reduces the occurrence of at least one bronchiectasis exacerbation during 12-month follow-up compared with matching placebo added to standard bronchiectasis care.\n\nParticipants will be randomized in a 1:1 allocation ratio to standard care plus matching placebo or standard care plus azithromycin. The primary analysis will follow the intention-to-treat (ITT) principle.\n\nThe AMBER trial is embedded within the Assiut University bronchiectasis translational research platform and is linked to the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework and the Bronchiectasis Phenotype Identification Model (BPIM). BASE and BPIM are not used for randomization stratification and will not modify the primary randomized comparison.\n\nThe locked Version 1.0 methodological disclosure document, protocol, and statistical analysis plan (SAP), primary sample-size source code, and endpoint-level sample-size support matrix are archived in Zenodo: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20178963.\n\nThe AMBER public preregistration is also available through the Open Science Framework (OSF) under Digital Object Identifier (DOI) 10.17605\u002FOSF.IO\u002FRE54V.",[27,28,29,30],"Non-cystic Fibrosis Bronchiectasis","Bronchiectasis Adult","Bronchiectasis","Bronchiectasis With Acute Exacerbation",[32,29,33,34,35,36,37,38,39,40],"Non-cystic fibrosis bronchiectasis (NCFB)","Bronchiectasis exacerbation","Exacerbation risk","azithromycin","macrolide therapy","double-blind placebo-controlled trial","randomized controlled trial (RCT)","12-month follow-up","Assiut University","NOT_YET_RECRUITING","2026-05-19",{"date":44,"type":45},"2026-05-27","ACTUAL",{"date":47,"type":21},"2026-05-21",{"date":49,"type":21},"2027-06-30",{"name":40,"class":51},"OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100638565","base-bronchiectasis-severity-and-exacerbation-risk-study-100638565","NCT07599839","BASE: Bronchiectasis Severity and Exacerbation Risk Study","BASE: Bronchiectasis Assessment of Severity and Exacerbations for Baseline Severity Classification and One-Year Exacerbation Risk Prediction in Non-Cystic Fibrosis Bronchiectasis","BASE","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Clinically stable or routinely assessed patients with non-cystic fibrosis bronchiectasis (NCFB) eligible for baseline severity and risk assessment.\n* Patients attending outpatient clinic, inpatient ward, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for prospective baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned 12-month follow-up for bronchiectasis exacerbation and outcome assessment.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent 12-month follow-up.\n* Acute life-threatening illness preventing safe enrollment or baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete the required baseline or Bronchiectasis Assessment of Severity and Exacerbations (BASE) assessment according to the study protocol.\n* Inability or unwillingness to complete planned 12-month follow-up.\n* Refusal to participate.",{"count":62,"type":21},750,"OBSERVATIONAL","Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by permanent bronchial dilatation, impaired mucus clearance, recurrent infection, airway inflammation, and repeated exacerbations. Existing bronchiectasis severity tools are clinically useful, but many depend on prior exacerbation history, hospitalization history, subjective symptom assessment, or culture-based microbiological classification.\n\nThis prospective observational cohort study aims to develop and validate the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework. BASE is designed to classify current bronchiectasis severity and predict 12-month exacerbation risk using objective baseline functional, radiological, oxygenation, and inflammatory variables. Detailed methodological specifications, including variable definitions, scoring architecture, endpoint hierarchy, development-validation governance, and analytical integrity rules, are archived in a restricted-access Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20143505\n\n.\n\nParticipants will receive routine clinical care, and no treatment or intervention will be assigned by the study protocol. Patients will be followed for 12 months to record bronchiectasis exacerbations, hospitalization, lung-function change, inflammatory marker change, and clinical outcomes. The Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework includes two linked baseline models: the BASE Severity model (BASE-S) for current bronchiectasis severity classification and the BASE Prognostic model (BASE-P) for prediction of 12-month exacerbation risk. Both models will be derived in the development cohort and applied unchanged to the validation cohort.",[29,27,30],[32,29,67,33,34,68,69,70,71],"Bronchiectasis severity","One-year exacerbation risk","Baseline risk prediction","Disease-signature model","Prospective observational cohort","RECRUITING","2026-05-15",{"date":75,"type":45},"2026-05-20",{"date":77,"type":45},"2025-09-11",{"date":79,"type":21},"2027-02-01",{"name":40,"class":51},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":52},"100639767","bronchiectasis-phenotype-identification-model-100639767","NCT07599969","Bronchiectasis Phenotype Identification Model","BPIM: Bronchiectasis Phenotype Identification Model for Supervised Baseline Translation of Latent Class Trajectory Analysis-Derived Phenotypes in Non-Cystic Fibrosis Bronchiectasis","BPIM","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for baseline disease-signature assessment within the Bronchiectasis Phenotype Identification Model (BPIM) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned longitudinal follow-up required for latent class trajectory analysis (LCTA) and Bronchiectasis Phenotype Identification Model (BPIM) validation.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment or reliable baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete required baseline disease-signature assessment according to the Bronchiectasis Phenotype Identification Model (BPIM) protocol.\n* Inability or unwillingness to complete planned longitudinal follow-up.\n* Refusal to participate.",{"count":62,"type":21},"The Bronchiectasis Phenotype Identification Model (BPIM) is a prospective observational development-validation study within the Assiut University bronchiectasis translational research platform.\n\nThe study evaluates whether latent class trajectory analysis (LCTA)-derived bronchiectasis phenotype classes can be translated into a supervised baseline classifier for adults with non-cystic fibrosis bronchiectasis (NCFB).\n\nLatent class trajectory analysis (LCTA) will first identify trajectory-derived phenotype classes using prospectively collected longitudinal disease-signature data. The Bronchiectasis Phenotype Identification Model (BPIM) will then be trained to predict the accepted latent class trajectory analysis (LCTA)-derived phenotype class using the locked baseline disease-signature architecture.\n\nThis study is observational and non-interventional. No treatment, medication, intervention, exposure, or management strategy is assigned by the protocol. All participants receive routine clinical care according to institutional practice and treating physician judgment.\n\nThe locked methodological disclosure, protocol, and deterministic statistical analysis plan are archived in the version-specific Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20157926.",[29,27,30],[32,29,93,33,34,68,69,70,71,94,95,96],"Bronchiectasis Phenotype Identification Model (BPIM)","Development-validation study","Latent class trajectory analysis (LCTA)","supervised phenotype classifier",{"date":75,"type":45},{"date":77,"type":45},{"date":100,"type":21},"2026-12-01",{"name":40,"class":51},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":63,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":120,"locationsCount":4},"100619592","impact-of-comorbidities-and-severity-on-outcomes-in-bronchiectasis-excerbations-100619592","NCT07346625","Impact of Comorbidities and Severity on Outcomes in Bronchiectasis Excerbations","Impact of Comorbiditries and Disease Severity on Clinical Outcomes of Patients With Acute Exacerbations of Bronchiectesis","Inclusion Criteria:\n\n* Adults (≥18 years) admitted with a diagnosis of \"Bronchiectasis with acute exacerbation\". The bronchiectasis exacerbation is diagnosed based on deterioration in three or more of the following main symptoms for 48h at least: cough, sputum volume or sputum consistency, purulent sputum, breathlessness or exercise tolerance, fatigue or malaise, hemoptysis, and the requirement of a change in the bronchiectasis treatment as determined by a clinician.\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age. Patients who refuse participation or whose medical records lack informed consent (if applicable).",{"count":110,"type":21},100,"1 Year","Acute exacerbations of bronchiectasis are associated with variable outcomes depending on patient factors. Comorbidities such as COPD, diabetes, and cardiovascular disease, as well as disease severity scores, significantly influence hospitalization rates, length of stay, need for intensive care, and mortality. Understanding these associations helps in risk stratification, guiding management, and improving prognosis in affected patients.",[30],"2026-01-07",{"date":116,"type":45},"2026-01-16",{"date":118,"type":21},"2026-02-01",{"date":100,"type":21},{"name":121,"class":51},"Sohag University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":52},"100532149","phase-4-bronchoscopic-levofloxacin-gentamicin-or-sham-for-acute-exacerbation-of-bronchiectasis-100532149","NCT06209047","Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis","A Randomized Sham-Controlled Trial of Bronchoscopic Levofloxacin and Gentamicin Versus Sham in Mechanically Ventilated Bronchiectasis: Acute and 1-Year Outcomes","Inclusion Criteria:\n\n* patients with bronchiectasis confirmed by high-resolution CT chest(HRCT)\n* patients with acute exacerbation of bronchiectasis who need antibiotic treatment at the hospital due to exacerbation\n* mechanically ventilated patients in the respiratory ICU\n* Age more than or equal to 18 years\n\nExclusion Criteria:\n\n* patients with active pulmonary tuberculosis\n* patients with allergic bronchopulmonary aspergillosis\n* patients who underwent interventional bronchoscopy for hemoptysis\n* age less than 18 years",{"count":130,"type":21},315,[24],"Randomized single-center trial evaluating whether bronchoscopic instillation of levofloxacin or gentamicin improves outcomes compared to a sham bronchoscopic procedure in adult ICU patients with non-cystic fibrosis bronchiectasis requiring invasive mechanical ventilation. The primary outcome is a ranked composite of in-hospital mortality and time to ventilator liberation. Safety and procedural adverse events are closely monitored.",[30],[29,135,136,137,138],"Bronchoscopy","Levofloxacin","Gentamicins","Steroids","2025-07-13",{"date":141,"type":45},"2025-07-17",{"date":143,"type":45},"2023-10-15",{"date":79,"type":21},{"name":40,"class":51},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":52},"100564189","exploring-how-viral-infections-affect-people-with-chronic-lung-disease-100564189","NCT06625944","Exploring How Viral Infections Affect People With Chronic Lung Disease","Prospective Cohort Study to Understand Impact of Viral Infection in Chronic Lung Disease","PRIVILEGE","Inclusion Criteria:\n\n* Adults with a physician confirmed diagnosis of chronic airway disease (e.g. COPD and bronchiectasis) according to established diagnostic criteria.\n\nAND\n\n\\- Prior history of exacerbation within last year (defined as requiring antibiotic and\u002For corticosteroids).\n\nExclusion Criteria:\n\n* Inability to complete daily symptom diaries and\u002For attend for clinical assessments.\n* Exacerbation within 4 weeks of study recruitment and\u002For clinical instability at the time of recruitment.\n* Pregnancy.",{"count":155,"type":21},180,"Many people with chronic lung disease have disease flare-ups. It was previously believed that these were mainly caused by bacteria but recent evidence suggests that viruses could be an important trigger. This study will recruit volunteers with chronic lung disease and take samples both when well (at baseline) and during flare-ups (exacerbations) to better understand the role of viruses in triggering exacerbations and also how the immune response is affected. The researchers will follow the volunteers\\' progress for up to two years. Whenever they get unwell they will take some samples (nose swabs, finger prick testing, phlegm sample) and post them to the researchers. Then, they will come in for a visit for more samples (blood tests, further swabs) and a review.",[28,30,158,159],"COPD (Chronic Obstructive Pulmonary Disease)","Respiratory Infection Virus",[161,162,29,163,164],"Natural Cohort","Prospective","Chronic Lung Disease","COPD","2025-07-09",{"date":167,"type":45},"2025-07-14",{"date":169,"type":45},"2024-11-01",{"date":171,"type":21},"2027-04",{"name":173,"class":51},"Imperial College London",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":188,"conditions":189,"keywords":193,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":52},"100587639","a-rhinovirus-challenge-study-to-investigate-exacerbations-and-immune-responses-in-bronchiectasis-100587639","NCT06931002","A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis","Human Bronchiectasis Rhinovirus Challenge to Define Immunopathogenesis of Exacerbation","BARRIER","Inclusion Criteria:\n\n* For healthy volunteers:\n\n  1\\) Age 18 to 65 years.\n* For bronchiectasis study subjects:\n\n  1. Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .\n  2. For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.\n\nExclusion Criteria:\n\n* For healthy volunteers and bronchiectasis study subjects:\n\n  1. Any medical co-morbidity impacting the study in the opinion of the medical team\n  2. Current smoking history within last 12 months or ex smoking history \\>5 pack years\n  3. Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)\n  4. Close contact with infants or elderly individuals either at home or workplace\n  5. Pregnancy or breastfeeding\n* For bronchiectasis study subjects:\n\n  1\\) Individuals with bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 2) Individuals with other significant chronic lung disease diagnoses (eg. interstitial lung disease) which would impact the study in the opinion of the medical team 4) FEV1 \\\u003C 50% predicted 8) Recent antibiotics for exacerbations within the preceding 6 weeks and prophylactic antibiotics (azithromycin or nebulised antibiotics) within preceding 4 weeks 9) Corticosteroid use (inhaled, nasal or systemic) within preceding 4 weeks.",true,"65 Years",{"count":185,"type":21},54,[187],"NA","The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are:\n\n* Does viral infection with the common cold lead to an exacerbation in bronchiectasis?\n* Does the immune response differ to that of a healthy participant?\n\nParticipants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.",[28,30,190,191,192],"Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa","Viral Infection","Rhinovirus Infection",[194,195,196],"bronchiectasis","rhinovirus","case control study","2025-07-04",{"date":165,"type":45},{"date":200,"type":45},"2024-07-24",{"date":202,"type":21},"2027-10-30",{"name":173,"class":51},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":52},"100595811","comparing-active-cycle-of-breathing-techniques-acbt-and-aerobika-in-treating-bronchiectasis-in-korea-100595811","NCT07037303","Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea","Comparison of Effectiveness Between Active Cycle of Breathing Techniques (ACBT) and Oscillating Positive Expiratory Pressure (OPEP, Aerobika) Device Assisted Treatment in Patients With Bronchiectasis in Korea : Randomized Controlled Trials","Inclusion Criteria:\n\n* 18 years of age or older\n* Patients diagnosed with bronchiectasis involving one or more lobes on chest computed tomography (CT)\n* Patients experiencing frequent exacerbations (3 or more exacerbations) within 1 year\n* Patients able and willing to use the Aerobika device (OPEP)\n\nExclusion Criteria:\n\n* Diagnosis of bronchiectasis due to cystic fibrosis\n* Traction bronchiectasis due to interstitial lung disease (ILD)\n* Pregnant patients\n* Patients with a history of OPEP device use\n* Patients who cannot tolerate increased breathing work\n* Hemodynamic instability (e.g., unstable blood pressure)\n* Patients with a past or current history of hemoptysis (pulmonary bleeding) and untreated pneumothorax",{"count":110,"type":21},[187],"Title:\n\nComparison of Effectiveness Between Active Cycle of Breathing Techniques (ACBT) and Oscillating Positive Expiratory Pressure (OPEP, Aerobika) Device Assisted Treatment in Patients With Bronchiectasis in Korea: A Randomized Controlled Trial\n\nPurpose:\n\nThis study aims to evaluate the effectiveness of Active Cycle of Breathing Techniques (ACBT) alone versus ACBT combined with an Oscillating Positive Expiratory Pressure (OPEP) device (Aerobika) in patients with bronchiectasis. The goal is to determine whether the combination therapy reduces the frequency of acute exacerbations and improves patient symptoms compared to ACBT alone.\n\nPrimary Questions:\n\nDoes the use of ACBT plus Aerobika reduce the number of acute exacerbations in patients with bronchiectasis who experience ≥3 exacerbations per year?\n\nWhat symptoms and adverse events are observed in participants using the Aerobika device?\n\nStudy Design:\n\nThis is a single-center, randomized, controlled clinical trial conducted at Chungbuk National University Hospital in Korea. 100 adult patients diagnosed with bronchiectasis and having ≥3 acute exacerbations within 1 year will be enrolled and randomized into two groups (1:1):\n\nActive Cycle of Breathing Technique (ACBT) group\n\nActive Cycle of Breathing Technique (ACBT) and Oscillatory Positive Expiratory Pressure (OPEP) group\n\nThe intervention period lasts 12 months, with clinic visits scheduled at 0, 1, 3, 6, 9, and 12 months.\n\nParticipation Involves:\n\nUse of ACBT with or without Aerobika daily for 12 months\n\nIn-person clinic visits every 1 to 3 months\n\nMonthly phone follow-ups to assess symptoms and adverse events\n\nCompletion of questionnaires (mMRC, BHQ, CAT) and clinical tests including PFT and laboratory tests\n\nTracking of exacerbation frequency, sputum volume, and quality",[29,30],[194,216,217],"aerobika","ACBT","2025-06-21",{"date":220,"type":45},"2025-06-25",{"date":222,"type":21},"2025-07-01",{"date":224,"type":21},"2028-07-01",{"name":226,"class":51},"Chungbuk National University Hospital",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":52},"100571907","value-of-bronchoalveolar-lavage-with-acetylcysteine-in-the-treatment-of-bronchiectasis-100571907","NCT06726356","Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.","Efficacy and Safety of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis with Infection in Adults: a Multicentre, Blinded, Randomised Controlled Study.","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years;\n2. Chest CT suggestive of bronchiectasis;\n3. meet the criteria for an acute exacerbation of bronchiectasis with symptoms such as cough, sputum, chest tightness or wheezing, and c. Patients who meet the criteria for an acute exacerbation of bronchiectasis with symptoms of cough, sputum, chest tightness or wheezing and who consent to bronchoscopy with bronchoalveolar lavage\n4. patients who agreed to participate in the study and signed an informed consent form;\n\nExclusion Criteria:\n\n1. Severe cardiopulmonary diseases, coagulation disorders, poor tolerance to anaesthesia, psychiatric disorders or severe neuroses that are contraindications to bronchoscopy;\n2. Intraoperative findings of decreased SPO2 or inability to tolerate bronchoscopy or inability to tolerate further bronchoalveolar lavage;\n3. Inability to co-operate with the study for any reason or in the opinion of the investigator, inappropriate for inclusion in the study for other reasons;\n4. Bronchoscopy of patients with significant intra-airway haemorrhage who may be at risk of exacerbation due to bronchoalveolar lavage;\n5. Patients with acetylcysteine allergy;\n6. Missing information;","80 Years",{"count":155,"type":21},[187],"Bronchiectasis is a clinical syndrome characterised by chronic cough, profuse sputum and\u002For intermittent haemoptysis, with or without shortness of breath and respiratory failure of varying severity, and abnormal thickening and dilatation of the bronchial walls as seen on lung imaging. Nebulised inhalation of N-acetylcysteine has been shown to significantly improve symptoms, shorten the length of hospital stay, reduce the rate of re-hospitalisation within six months, and improve lung function in patients with bronchiectasis with a high degree of safety. There have been no studies on the efficacy and safety of bronchoscopic irrigation with N-acetylcysteine solution in the treatment of bronchiectasis. The aim of this study was to investigate whether bronchoscopic acetylcysteine lavage combined with conventional treatment is more beneficial to patients with bronchiectasis than conventional treatment combined with conventional bronchoalveolar lavage and conventional treatment without bronchoscopy, respectively.",[239],"Bronchiectasis with Acute Exacerbation",[241],"bronchiectasis; acetylcysteine; bronchoalveolar lavage; Bronchoscopic airway clearance therapy","2024-12-09",{"date":244,"type":45},"2024-12-10",{"date":246,"type":45},"2024-08-14",{"date":248,"type":21},"2026-07-30",{"name":250,"class":251},"First Affiliated Hospital of Ningbo University","NETWORK"]